Cognito Therapeutics
Cognito Therapeutics58About
What does Cognito Therapeutics do?
Cognito Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic approach for Alzheimer's disease. Their lead product candidate, Spectris™, is a non-invasive, wearable neurostimulation device designed to treat cognitive decline associated with Alzheimer's. The company aims to address the underlying pathology of the disease by modulating brain activity.
What is Cognito Therapeutics's revenue?
StartupHub estimates Cognito Therapeutics's annual revenue at $29.2M (range $16.0M to $75.5M, 44% confidence), based on comparable companies in the sector.
What is Cognito Therapeutics's valuation?
StartupHub estimates Cognito Therapeutics's effective valuation at $451.4M (range $316.0M to $586.8M, 41% confidence), based on comparable companies in the sector.
How much funding has Cognito Therapeutics raised?
Cognito Therapeutics has raised a total of $213M in funding. The most recent round on record is Series C.
Where is Cognito Therapeutics headquartered?
Cognito Therapeutics is headquartered in Boston, Massachusetts, USA.
When was Cognito Therapeutics founded?
Cognito Therapeutics was founded in 2011.
What industry does Cognito Therapeutics operate in?
Cognito Therapeutics operates in Biotechnology, Medical Devices, Neuroscience, Healthcare.
No comments yet. Be the first to share your take.